RT Journal Article
SR Electronic
T1 Cranial nerve involvement in patients with MOG antibody–associated disease
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e543
DO 10.1212/NXI.0000000000000543
VO 6
IS 2
A1 Alvaro Cobo-Calvo
A1 Xavier Ayrignac
A1 Philippe Kerschen
A1 Philippe Horellou
A1 Francois Cotton
A1 Pierre Labauge
A1 Sandra Vukusic
A1 Kumaran Deiva
A1 Ché Serguera
A1 Romain Marignier
YR 2019
UL http://nn.neurology.org/content/6/2/e543.abstract
AB Objective To describe clinical and radiologic features of cranial nerve (CN) involvement in patients with myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) and to assess the potential underlying mechanism of CN involvement using a nonhuman primate (NHP) model.Methods Epidemiologic, clinical, and radiologic features from a national cohort of 273 MOG-IgG–positive patients were retrospectively reviewed for CN involvement between January 2014 and January 2018. MOG-IgG binding was evaluated in CNS, CN, and peripheral nerve tissues from NHP.Results We identified 3 MOG-IgG–positive patients with radiologic and/or clinical CN involvement. Two patients displayed either trigeminal or vestibulocochlear nerve lesions at the root level, and the remaining patient had an oculomotor nerve involvement at the root exit and at the cisternal level. Additional CNS involvement was found in all 3 patients. None of the 3 patients' sera recognized MOG expression in CN of NHP.Conclusion Craneal nerve involvement can coexist in patients with MOG antibody disease, although the underlying pathophysiology remains elusive.AQP4=aquaporin-4; CN=cranial nerve; hMOG=human MOG; MBP=myelin basic protein; MFI=mean fluorescence intensity; MOG=myelin oligodendrocyte glycoprotein; MTP=methylprednisolone; NHP=nonhuman primate; NMOSD=neuromyelitis optica spectrum disorder; OCB=oligoclonal band; OFSEP=Observatoire Français de la Sclérose en Plaques; RT=room temperature